U.S. market Closed. Opens in 21 hours 30 minutes

NAMS | NewAmsterdam Pharma Company N.V. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 21.57 - 22.47
52 Week Range 15.19 - 27.29
Beta 1.03
Implied Volatility 113.43%
IV Rank 19.57%
Day's Volume 682,208
Average Volume 883,333
Shares Outstanding 109,818,000
Market Cap 2,389,639,680
Sector Healthcare
Industry Biotechnology
IPO Date 2021-02-09
Valuation
Profitability
Growth
Health
P/E Ratio -8.50
Forward P/E Ratio N/A
EPS -2.56
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 62
Country Netherlands
Website NAMS
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
*Chart delayed
Analyzing fundamentals for NAMS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see NAMS Fundamentals page.

Watching at NAMS technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on NAMS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙